Breaking News Instant updates and real-time market news.

BLUE

Bluebird Bio

$136.36

3.93 (2.97%)

, SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

08:20
11/06/18
11/06
08:20
11/06/18
08:20

RBC Capital to hold a bus tour

Biotech Bus Tour travels throughout Boston on November 6.

BLUE

Bluebird Bio

$136.36

3.93 (2.97%)

SAGE

Sage Therapeutics

$126.62

-10.64 (-7.75%)

SRPT

Sarepta

$139.53

-6.32 (-4.33%)

  • 06

    Nov

  • 06

    Nov

  • 12

    Nov

  • 27

    Nov

  • 01

    Dec

  • 03

    Dec

  • 13

    Dec

  • 19

    Dec

BLUE Bluebird Bio
$136.36

3.93 (2.97%)

11/02/18
PIPR
11/02/18
NO CHANGE
PIPR
Overweight
Piper says ASH meeting 'will be major' for Bluebird Bio
Piper Jaffray analyst Tyler Van Buren said it "makes sense" that Bluebird Bio has reached an agreement with the FDA to adjust the HGB-206 primary efficacy endpoint to be based on HbA-T87Q expression and total hemoglobin. However, he is awaiting additional clinical data at ASH or in the future to better gauge the probability of success for the pivotal program. While noting that bb2121 is the furthest anti-BCMA program in development, he also prefers to await "the wealth of data" to be reported from other anti-BCMA programs at ASH to more accurately assess bb2121's market opportunity, Van Buren tells investors. The analyst, who sees ASH being "a major event for Bluebird," keeps an Overweight rating on the shares.
11/05/18
JANY
11/05/18
UPGRADE
JANY
Buy
Bluebird Bio upgraded to Buy from Neutral at Janney Montgomery Scott
11/05/18
WEDB
11/05/18
NO CHANGE
Target $166
WEDB
Outperform
Bluebird Bio price target lowered to $166 from $204 at Wedbush
Wedbush analyst David Nierengarten lowered his price target for Bluebird Bio to $166 from $204, while reiterating an Outperform rating on the shares. The analyst looks forward to a catalyst-filled ASH for the company that will be highlighted by a first look at next-gen BCMA-CAR-T candidate bb21217 in multiple myeloma and initial results from its Phase 1 study of shRNAmiR-LLV gene therapy for sickle cell disease. Nierengarten also notes that Bluebird has provided an update on its SCD registration strategy following the recent FDA-ASH SCD clinical endpoints workshop. He believes that the update increases the program's probability of success, but also pushes out the program's development timeline at least two years.
11/05/18
JANY
11/05/18
UPGRADE
Target $170
JANY
Buy
Janney Montgomery Scott upgrades Bluebird Bio to Buy ahead of ASH
As previously reported, Janney Montgomery Scott analyst Yun Zhong upgraded Bluebird Bio to Buy from Neutral, stating that he does not believe any company-specific reasons were behind the weakness seen in the stock since the end of August. With the stock having lost over 40% from its March peak, Zhong now sees a much more favorable valuation and he also expects more detailed data to be provided at the ASH conference driving further stock outperformance. Zhong maintains a $170 fair value estimate on Bluebird Bio shares.
SAGE Sage Therapeutics
$126.62

-10.64 (-7.75%)

10/17/18
STFL
10/17/18
NO CHANGE
Target $239
STFL
Buy
Stifel confident in approval of Sage Therapeutics' brexanolone ahead of AdComm
Ahead of an FDA advisory committee meeting on Nov 2 to review brexanolone, Stifel analyst Paul Matteis said he is confident in FDA approval and expects the debate on the drug to be centered on labeling, REMS and necessary monitoring requirements. While noting that brexanolone comprises a minority of his Sage valuation, Matteis said the most important thing for the stock is that the panel is both positive and doesn't raise any sort of issue that would read negatively onto SAGE-217, which comprises the majority of his Sage valuation. He maintains a Buy rating and $239 price target on Sage Therapeutics shares.
10/31/18
BMOC
10/31/18
NO CHANGE
Target $203
BMOC
Outperform
BMO sees approval for Sage after Zulresso briefing docs
The FDA this morning released briefing documents for Friday's panel meeting to discuss Sage Therapeutics' Zulresso to treat postpartum depression. It appears the FDA is satisfied with the drug's efficacy and overall tolerability and recognizes a significant unmet need for postpartum depression, BMO Capital analyst Gary Nachman tells investors in a research note. He believes Zulresso will likely be approved on the December 19 FDA action date. Nachman adds, however, that there are some questions on the recommended dosing, since initially the lower dose appears more effective but the doses start to separate during titration when going out beyond 24 hours. He has an Outperform rating on Sage Therapeutics with a $203 price target. The stock in early trading is up 1% to $122.47.
10/31/18
10/31/18
NO CHANGE
Target $206

Overweight
Sage briefing docs 'clearly supportive of approval,' says Piper Jaffray
In a midday research note partially titled "Nothing Too Spooky in Brex Briefing Docs," Piper Jaffray analyst Danielle Brill says this morning's FDA's briefing documents for Sage Therapeutics' brexanolone were overall supportive of approval for postpartum depression. The agency appears comfortable with brexanolone's efficacy, and focused on recommended dosing as a key topic of discussion, Brill writes in a note to investors. The major safety concern, loss of consciousness during infusion which occurred in 4% of women treated, does not appear to be barring of approval, says the analyst. However, Brill adds that while she views the tone of the docs as "clearly supportive of approval," prohibiting administration "at-home" has "obvious negative implications for commercial potential." She has an Overweight rating on Sage Therapeutics with a $206 price target. The stock in midday trading is up 6%, or $7.77, to $129.00.
11/01/18
ADAM
11/01/18
NO CHANGE
Target $220
ADAM
Buy
Sage Therapeutics FDA briefing documents read 'ok,' says Canaccord
Canaccord analyst Sumant Kulkarni noted the FDA posted its briefing documents related to Sage Therapeutics' brexanolone ahead of the advisory committee meeting on the product scheduled for November 2. The analyst said they appear "ok" and said the drug could be the first approved for the treatment of post-partum depression. The analyst said with the stock down roughly 10% since the FDA confirmed the date of the AdCom meeting, he is telling investors to buy the shares. Kulkarni reiterated his Buy rating and $220 price target on Sage Therapeutics shares.
SRPT Sarepta
$139.53

-6.32 (-4.33%)

10/16/18
JMPS
10/16/18
NO CHANGE
Target $270
JMPS
Outperform
JMP likes risk-reward in Sarepta deal for MPS IIIA gene therapy
After Sarepta announced a deal to gain U.S. commercial rights to a potential gene therapy treatment for Mucopolysaccharidosis type IIIA, or MPS IIIA, JMP Securities analyst Liisa A. Bayko said she likes the risk-reward given the relatively limited committed capital and development responsibilities in exchange for full U.S. rights to a late-stage "shot on goal." The analyst, who noted this represents Sarepta's fourth gene therapy deal this year, keeps an Outperform rating and $270 price target on Sarepta shares.
10/25/18
PIPR
10/25/18
NO CHANGE
Target $168
PIPR
Overweight
Sarepta price target lowered to $168 from $189 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff lowered his price target for Sarepta Therapeutics to $168 from $189 and keeps an Overweight rating on the name following the company's Q3 results. Exondys51 sales were in-line at $78.5M in Q3 and management reiterated guidance of $295-$305M for this year, Tenthoff tells investors in a research note. He believes Exondys51 sales of $300M this year "are plateauing" and now forecasts $344M of sales in 2019. The analyst, however, says micro-dystrophin GeneRx is advancing and could treat up to 70% of Duchenne muscular dystrophy boys. He thinks this will erode exon-skipping sales upon approval in 2020.
11/06/18
SBSH
11/06/18
INITIATION
Target $25
SBSH
Sell
Solid Biosciences initiated with a Sell at Citi
Citi analyst Joel Beatty started Solid Biosciences (SLDB) with a Sell rating and $25 price target. The analyst believes the gene therapy agents in clinical development for Duchenne muscular dystrophy by Sarepta (SRPT) and Pfizer (PFE) will leave little market share to Solid Bio's SGT-001. The analyst forecasts Sarepta capturing the largest share of the DMD gene therapy market, followed by Pfizer, and then Solid.
11/06/18
SBSH
11/06/18
NO CHANGE
Target $188
SBSH
Buy
Sarepta price target raised to $188 from $174 at Citi
Citi analyst Joel Beatty raised his price target for Sarepta Therapeutics to $188 following an in-depth analysis of the three Duchenne muscular dystrophy gene therapy programs in development. Based on the analysis, the analyst has a higher conviction that Sarepta will have "significant market share." He keeps a Buy rating on the shares.

TODAY'S FREE FLY STORIES

VLKAY

Volkswagen

$0.00

(0.00%)

, GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

15:45
11/18/18
11/18
15:45
11/18/18
15:45
Periodicals
Volkswagen CEO says Waymo has 1/2-year head start, Reuters reports »

Volkwagen (VLKAY) is up…

VLKAY

Volkswagen

$0.00

(0.00%)

GOOG

Alphabet

$1,062.01

-2.73 (-0.26%)

GOOGL

Alphabet Class A

$1,069.13

-2.09 (-0.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

15:21
11/18/18
11/18
15:21
11/18/18
15:21
Hot Stocks
AT&T, Fox Networks renew multi-year deal across distribution platforms »

AT&T (T) and Fox…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 04

    Dec

AAPL

Apple

$193.42

2 (1.04%)

13:35
11/18/18
11/18
13:35
11/18/18
13:35
Periodicals
Apple CEO views new regulations as 'inevitable,' Axios reports »

Apple CEO Tim Cook says…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSRGY

Nestle

$0.00

(0.00%)

, RIO

Rio Tinto

$50.94

0.89 (1.78%)

13:05
11/18/18
11/18
13:05
11/18/18
13:05
Periodicals
Nespresso, Rio Tinto joining forces to make coffee pods greener, Reuters says »

Nespresso, part of food…

NSRGY

Nestle

$0.00

(0.00%)

RIO

Rio Tinto

$50.94

0.89 (1.78%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$1.11

-0.095 (-7.92%)

12:54
11/18/18
11/18
12:54
11/18/18
12:54
Hot Stocks
Sonoma Pharmaceuticals announces pricing of public offering of units »

Sonoma Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 04

    Dec

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/18/18
11/18
04:55
11/18/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

PDVW

pdvWireless

$39.84

0.06 (0.15%)

16:30
11/17/18
11/17
16:30
11/17/18
16:30
Conference/Events
pdvWireless management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBS

CBS

$57.49

0.23 (0.40%)

16:28
11/17/18
11/17
16:28
11/17/18
16:28
Conference/Events
CBS management to meet with Morgan Stanley »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

THS

TreeHouse

$51.92

0.72 (1.41%)

, CAG

Conagra Brands

$33.09

0.66 (2.04%)

12:54
11/17/18
11/17
12:54
11/17/18
12:54
Periodicals
Treehouse Foods stock may have room to gain, Barron's says »

Treehouse Foods (THS)…

THS

TreeHouse

$51.92

0.72 (1.41%)

CAG

Conagra Brands

$33.09

0.66 (2.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$194.23

1.83 (0.95%)

12:51
11/17/18
11/17
12:51
11/17/18
12:51
Periodicals
Amgen may be 'a remedy' for tougher times, Barron's says »

Amgen may be a stock that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 01

    Dec

  • 02

    Dec

  • 03

    Dec

  • 03

    Dec

AAPL

Apple

$193.42

2 (1.04%)

, LITE

Lumentum

$41.50

0.46 (1.12%)

12:47
11/17/18
11/17
12:47
11/17/18
12:47
Periodicals
Apple stock could continue to slide, Barron's says »

Apple's (AAPL) stock…

AAPL

Apple

$193.42

2 (1.04%)

LITE

Lumentum

$41.50

0.46 (1.12%)

QRVO

Qorvo

$66.32

1.18 (1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APC

Anadarko

$56.39

0.9 (1.62%)

, RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

12:41
11/17/18
11/17
12:41
11/17/18
12:41
Periodicals
Investors may find bargains among oil, natural gas stocks, Barron's says »

Investors have been…

APC

Anadarko

$56.39

0.9 (1.62%)

RDS.B

Royal Dutch Shell

$63.97

0.19 (0.30%)

RDS.A

Royal Dutch Shell

$62.02

0.34 (0.55%)

XOM

Exxon Mobil

$78.99

0.81 (1.04%)

CVX

Chevron

$119.14

2.18 (1.86%)

BP

BP

$40.85

-0.3 (-0.73%)

EOG

EOG Resources

$105.21

3.57 (3.51%)

OXY

Occidental Petroleum

$73.32

0.71 (0.98%)

COG

Cabot Oil & Gas

$25.73

0.09 (0.35%)

EQT

EQT Corporation

$16.62

-0.55 (-3.20%)

HAL

Halliburton

$32.46

0.02 (0.06%)

SLB

Schlumberger

$48.24

0.17 (0.35%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Jan

  • 22

    Jan

LB

L Brands

$35.28

-0.41 (-1.15%)

, JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

12:34
11/17/18
11/17
12:34
11/17/18
12:34
Periodicals
Kohl's, Target set to thrive this holiday season, Barron's says »

Store chains have been…

LB

L Brands

$35.28

-0.41 (-1.15%)

JCP

J.C. Penney

$1.29

-0.08 (-5.84%)

TJX

TJX

$51.47

-0.98 (-1.87%)

BBY

Best Buy

$66.41

-1.34 (-1.98%)

TIF

Tiffany

$106.48

0.52 (0.49%)

HD

Home Depot

$177.11

-0.25 (-0.14%)

TGT

Target

$79.67

-1.09 (-1.35%)

KSS

Kohl's

$72.48

-0.7 (-0.96%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 28

    Nov

  • 04

    Dec

  • 05

    Dec

  • 03

    Mar

T

AT&T

$30.30

0.18 (0.60%)

, FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

09:18
11/17/18
11/17
09:18
11/17/18
09:18
OnTheFly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

T

AT&T

$30.30

0.18 (0.60%)

FOX

21st Century Fox

$47.73

-0.1 (-0.21%)

FOXA

21st Century Fox

$48.18

-0.11 (-0.23%)

AMZN

Amazon.com

$1,593.59

-26.41 (-1.63%)

CMCSA

Comcast

$38.60

0.11 (0.29%)

CMCSK

Comcast

$0.00

(0.00%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.46

-0.12 (-0.72%)

F

Ford

$9.05

-0.26 (-2.79%)

GM

General Motors

$35.76

0.21 (0.59%)

HMC

Honda

$28.21

0.01 (0.04%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$116.87

-0.02 (-0.02%)

VLKAY

Volkswagen

$0.00

(0.00%)

NYT

New York Times

$26.30

-0.2 (-0.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

  • 03

    Dec

  • 04

    Dec

  • 13

    Dec

  • 23

    Jan

  • 25

    Apr

  • 24

    Jul

  • 23

    Oct

NVS

Novartis

$87.74

0.52 (0.60%)

, DBVT

DBV Technologies

$16.70

0.31 (1.89%)

04:55
11/17/18
11/17
04:55
11/17/18
04:55
Conference/Events
American College of Allergy, Asthma & Immunology to hold a meeting »

2018 ACAAI Meeting will…

NVS

Novartis

$87.74

0.52 (0.60%)

DBVT

DBV Technologies

$16.70

0.31 (1.89%)

REGN

Regeneron

$345.10

3.56 (1.04%)

SHPG

Shire

$175.59

-3.39 (-1.89%)

TEVA

Teva

$22.25

-0.37 (-1.64%)

SNY

Sanofi

$45.11

0.56 (1.26%)

GSK

GlaxoSmithKline

$40.35

-0.06 (-0.15%)

AZN

AstraZeneca

$40.67

-0.685 (-1.66%)

CHD

Church & Dwight

$65.42

-0.39 (-0.59%)

BSX

Boston Scientific

$37.22

0.75 (2.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 30

    Nov

  • 02

    Dec

  • 03

    Dec

  • 21

    Dec

  • 28

    Jan

  • 11

    Mar

  • 22

    Mar

  • 28

    Apr

  • 13

    May

MSI

Motorola Solutions

$129.97

0.72 (0.56%)

18:48
11/16/18
11/16
18:48
11/16/18
18:48
Hot Stocks
Motorola Solutions: ITC confirms Hytera products infringe Motorola patents »

Motorola Solutions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Nov

  • 18

    Dec

  • 19

    Dec

PCG

PG&E

$24.39

6.62 (37.25%)

18:23
11/16/18
11/16
18:23
11/16/18
18:23
Periodicals
CPUC isn't ruling out board shuffle, breakup for PG&E, Bloomberg says »

The California Public…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ABX

Barrick Gold

$13.04

0.05 (0.38%)

18:00
11/16/18
11/16
18:00
11/16/18
18:00
Periodicals
Barrick Gold looking to add more copper, bullion assets, Reuters reports »

Barrick Gold is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WTR

Aqua America

$33.05

0.165 (0.50%)

17:57
11/16/18
11/16
17:57
11/16/18
17:57
Hot Stocks
Aqua America CEO acquires over 25,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

, XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

17:39
11/16/18
11/16
17:39
11/16/18
17:39
General news
Week ending ETF scorecard: Real Estate leads, Consumer Discretionary slumps »

S&P500 SECTORS: Real…

XLRE

Real Estate SPDR

$33.45

0.445 (1.35%)

XLB

S&P Select Materials SPDR

$55.23

0.53 (0.97%)

XLU

Utilities SPDR

$54.86

0.77 (1.42%)

XLI

Industrial Select Sector SPDR

$72.00

(0.00%)

XLV

Health Care Select Sector SPDR

$92.05

0.91 (1.00%)

XLF

Financial Select Sector

$26.78

0.03 (0.11%)

XLP

Consumer Staples Sector SPDR

$56.04

0.15 (0.27%)

XLE

Energy Select Sector SPDR

$67.23

0.76 (1.14%)

XLC

Communication Services Select Sector SPDR Fund

$44.88

-0.2 (-0.44%)

XLK

Technology Select Sector SPDR

$68.22

-0.1 (-0.15%)

XLY

Consumer Discretionary Sector SPDR

$106.37

-0.43 (-0.40%)

GLD

SPDR Gold Shares

$115.56

0.82 (0.71%)

SLV

iShares Silver Trust

$13.55

0.115 (0.86%)

USO

United States Oil Fund

$12.07

0.08 (0.67%)

UNG

United States Natural Gas Fund

$35.43

3.63 (11.42%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.24

-0.27 (-0.32%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$111.73

0.23 (0.21%)

TLT

iShares 20+ Year Treasury Bond Fund

$114.65

0.61 (0.53%)

IEF

iShares 7-10 Year Treasury Bond ETF

$101.13

0.3 (0.30%)

SHY

iShares 1-3 Year Treasury Bond

$83.13

0.08 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AQST

Aquestive Therapeutics

$17.02

0.23 (1.37%)

17:36
11/16/18
11/16
17:36
11/16/18
17:36
Hot Stocks
Aquestive receives CRL from FDA for tadalafil oral film »

Aquestive Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jan

DAKT

Daktronics

$7.67

0.07 (0.92%)

17:35
11/16/18
11/16
17:35
11/16/18
17:35
Hot Stocks
Daktronics adopts new shareholder rights agreement »

Daktronics announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

TI

Telecom Italia

$6.02

0.12 (2.03%)

17:33
11/16/18
11/16
17:33
11/16/18
17:33
Periodicals
Gubitosi viewed as frontrunner for Telecom Italia CEO job, Reuters says »

Veteran Italian manager…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAXR

Maxar Technologies

$18.77

-0.59 (-3.05%)

17:30
11/16/18
11/16
17:30
11/16/18
17:30
Hot Stocks
Maxar Technologies shareholders approve U.S. domestication »

Maxar Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLUG

Plug Power

$1.83

(0.00%)

17:28
11/16/18
11/16
17:28
11/16/18
17:28
Syndicate
Breaking Syndicate news story on Plug Power »

Plug Power files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.